No Detail Found!

FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.

Author(s)
Khalil Ullah Hashmi Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Badshah Khan Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Parvez Ahmed Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Shahid Raza Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Hamid Iqbal Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Hamid Saeed Malik Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Masood Anwar Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Iftikhar Hussain Combined Military Hospital, Rawalpindi, Pakistan
Ahsan Mahmood Combined Military Hospital, Rawalpindi, Pakistan
Abstract
Objective: To evaluate the efficacy and toxicity profile of the combination of fludarabine, high dose cytarabine, idarubicin, and granulocyte colony stimulating factor in refractory relapsed cases of acute leukaemia, a study is being conducted at Armed Forces Bone Marrow Transplant Centre (AFBMTC) Rawalpindi since January 2003. Data up to June 2004 (early report) is being presented. Methods: Twelve Patients with refractory/relapsed (Ref/Rel) acute leukaemia (AL) were treated with fludarabine 30mg/m2 and cytosine arabinoside (AraC) Arac 2 g/m2 for 5 days, idarubicin 10mg/m2 for 3 days, and granulocyte colony stimulating factor G-CSF 5 micro g/kg from day 0 till neutrophil recovery (ANC >1.0 x 109/I). Response was evaluated by bone marrow examination on day 20-post chemotherapy. Results: Patients included were refractory acute lymphoblastic leukaemia (ALL) (n=2), relapsed ALL (n=3), refractory acute myeloid leukaemia (AML) (n=3), secondary AML (n=2) relapsed AML (n=1) and acute undifferentiated leukaemia (AUL) (n=1). Complete remission (CR) was achieved in 8 (66.6%) patients. Three (25%) patients died of post chemotherapy complications and one patient failed to achieve remission. Out of 8 patients who achieved CR, 4 underwent allogeneic bone marrow transfusion (BMT), 1 is being evaluated for the same, 1 received idorubicin, AraC and etopuside (ICE) and high dose AraC, 1 did not receive further chemotherapy and 1 relapsed two months after remission. Seven patients are still in CR after a median follow up of 8 months (range 3-18). Major complications encountered were diarrhoea, mucositis, toxic ileus, transient hepatic toxicity, fungal and bacterial infections. Conclusion: In our experience, FLAG-IDA is well tolerated and effective regimen in relapsed / refractory acute leukaemias. The toxicity is acceptable, enabling most patients to receive further treatment, including transplantation procedures.
Publication Details
Page(s) 234-238
DOI DOI not available
Published Journal: Journal of Pakistan Medical Association, Volume: 55, Issue: 6, Year: 2005

Request the full text from PASTIC

0

Citations

0

Downloads

65

Views